Dharani Sathish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dharani Sathish has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Mansoor Ali Khan
Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX 77843, USA
2 shared publications Panakanti Pavan Kumar
2 shared publicationsSubedari Himabindu
2 shared publications- Ziyaur Rahman
Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, USA
2 shared publications Athukuri Bharagavi Latha
Centre for Biopharmaceutics and Pharmacokinetics, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, AP, India
1 shared publication- Dai Lu
Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX 77843, USA
1 shared publication
Latest Publications
- 23 December 2021
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 23 (1) , 1-12
Preparation and Characterization of Stable Amorphous Glassy Solution of BCS II and IV Drugs
The focus of the present investigation was to develop amorphous glassy solutions (AGSs) of BCS Class II and IV drugs using sucrose acetate isobutyrate (SAI
- 23 December 2021
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 23 (1) , 1-12
Preparation and Characterization of Stable Amorphous Glassy Solution of BCS II and IV Drugs
The focus of the present investigation was to develop amorphous glassy solutions (AGSs) of BCS Class II and IV drugs using sucrose acetate isobutyrate (SAI
- 1 September 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 607, 120889
Ultra-long acting prodrug of dolutegravir and delivery system – Physicochemical, pharmacokinetic and formulation characterizations
- 1 September 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 607, 120889
Ultra-long acting prodrug of dolutegravir and delivery system – Physicochemical, pharmacokinetic and formulation characterizations
- 31 January 2014
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 8 (3) , 206-214
Preparation and Evaluation of Novel Expandable Drug Delivery System with Captopril
Aims: The purpose of this research is to develop a novel expandable gastroretentive dosage form (GRDF), based on an unfolding mechanism. It consists of a drug loaded bilayer polymeric film, folded into a hard gelatin capsule. Gastric retention is achieved due to unfolding of the dosage form within 15-20 min. Captopril is selected as the drug candidate for this work. Due to its narrow absorption window, Captopril has to be administered to the upper parts of the intestine in order to maintain sustained therapeutic levels. This may be achieved by a GRDF. Methodolgy: Films were prepared by solvent-casting technique using Ethyl cellulose, HPMC E15 and Eudragit RLPO as polymers and dibutyl-phthalate as the plasticizer in both layers. The film with zigzag folding in the capsule was shown to unfold in the gastric juice and provide drug release up to 12 h in the acidic medium. The films were evaluated for weight & thickness variation, mechanical properties, in vitro drug release and unfolding behaviour based on the mechanical shape memory of polymers. Absence of drug polymer interaction and uniform drug dispersion in the polymeric layers was revealed by DSC, XRD and SEM studies. The GRDF location in the gastrointestinal tract was determined by X-ray studies. Results: X-ray studies revealed that the GRDF is retained in the stomach up to 6± 0.5 h in fasting condition and 8 h in fed state. Conclusion: The polymers used in the development of GRDFs were safe and proper combination of these polymers will yield a novel expandable GRDF with good in vitro drug release in acidic media, mechanical properties, unfolding behaviour. These outcomes demonstrate that the GRDF may be used to improve Captopril therapy and can be applied to extend the absorption of other narrow absorption window drugs that require continuous input.
- 31 January 2014
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 8 (3) , 206-214
Preparation and Evaluation of Novel Expandable Drug Delivery System with Captopril
Aims: The purpose of this research is to develop a novel expandable gastroretentive dosage form (GRDF), based on an unfolding mechanism. It consists of a drug loaded bilayer polymeric film, folded into a hard gelatin capsule. Gastric retention is achieved due to unfolding of the dosage form within 15-20 min. Captopril is selected as the drug candidate for this work. Due to its narrow absorption window, Captopril has to be administered to the upper parts of the intestine in order to maintain sustained therapeutic levels. This may be achieved by a GRDF. Methodolgy: Films were prepared by solvent-casting technique using Ethyl cellulose, HPMC E15 and Eudragit RLPO as polymers and dibutyl-phthalate as the plasticizer in both layers. The film with zigzag folding in the capsule was shown to unfold in the gastric juice and provide drug release up to 12 h in the acidic medium. The films were evaluated for weight & thickness variation, mechanical properties, in vitro drug release and unfolding behaviour based on the mechanical shape memory of polymers. Absence of drug polymer interaction and uniform drug dispersion in the polymeric layers was revealed by DSC, XRD and SEM studies. The GRDF location in the gastrointestinal tract was determined by X-ray studies. Results: X-ray studies revealed that the GRDF is retained in the stomach up to 6± 0.5 h in fasting condition and 8 h in fed state. Conclusion: The polymers used in the development of GRDFs were safe and proper combination of these polymers will yield a novel expandable GRDF with good in vitro drug release in acidic media, mechanical properties, unfolding behaviour. These outcomes demonstrate that the GRDF may be used to improve Captopril therapy and can be applied to extend the absorption of other narrow absorption window drugs that require continuous input.
- 1 September 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 8 (2) , 121-131
Formulation and Ex Vivo Evaluation of Buccal Tablets of Isradipine in a β- Cyclodextrin Complex to Improve the Photostability
Delivery of hydrophobic drugs via buccal route is a challenging approach. Isradipine (IDP) is a highly hydrophobic drug and is practically insoluble in water. Though the log p value of Isradipine permits the drug to pass through buccal membrane, the amount of drug delivered is low. The aim of present investigation is to develop buccal tablets containing Isradipine complexed with a β-cyclodextrin. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies were used to examine the physicochemical properties of the inclusion complexes. Based on the solubility experiments, the 1:2 molar ratio (Isradipine:β-Cyclodextrin) has given good results. From the photostability studies it was concluded that Isradipine in the inclusion complex was more stable than pure Isradipine. Addition of βCD to the matrix increased the flux by increasing the solubility of drug, thus improving the diffusible form of the drug species at the tablet membrane interface. The flux (FS5) was found to be increased by 1.833 folds with a permeability coefficient of 0.022 cm h-1. Moreover Isradipine undergoes extensive hepatic metabolism. Thus formulating a buccal delivery system of Isradipine with βCD may improve the bioavailability and photostability of the drug along with patient compliance.
- 1 September 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 8 (2) , 121-131
Formulation and Ex Vivo Evaluation of Buccal Tablets of Isradipine in a β- Cyclodextrin Complex to Improve the Photostability
Delivery of hydrophobic drugs via buccal route is a challenging approach. Isradipine (IDP) is a highly hydrophobic drug and is practically insoluble in water. Though the log p value of Isradipine permits the drug to pass through buccal membrane, the amount of drug delivered is low. The aim of present investigation is to develop buccal tablets containing Isradipine complexed with a β-cyclodextrin. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies were used to examine the physicochemical properties of the inclusion complexes. Based on the solubility experiments, the 1:2 molar ratio (Isradipine:β-Cyclodextrin) has given good results. From the photostability studies it was concluded that Isradipine in the inclusion complex was more stable than pure Isradipine. Addition of βCD to the matrix increased the flux by increasing the solubility of drug, thus improving the diffusible form of the drug species at the tablet membrane interface. The flux (FS5) was found to be increased by 1.833 folds with a permeability coefficient of 0.022 cm h-1. Moreover Isradipine undergoes extensive hepatic metabolism. Thus formulating a buccal delivery system of Isradipine with βCD may improve the bioavailability and photostability of the drug along with patient compliance.
- Open Access
- 1 January 2012
- Published by Medknow in Archives Of Pharmacy Practice
- Vol. 3 (3) , 223
Effect of polymers on in-vitro performance of eplerenone sustained release matrix tablets
Arch Pharma Pract, Official publication of Archives of Global Professionals
- 1 January 2012
- Published by Medknow in Archives Of Pharmacy Practice
- Vol. 3 (3) , 223
Open AccessEffect of polymers on in-vitro performance of eplerenone sustained release matrix tablets
Arch Pharma Pract, Official publication of Archives of Global Professionals
- 1 December 2010
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 25 (1-4) , 3-16
P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions
P-Glycoprotein (P-gp), the most extensively studied ATP-binding cassette transporter, functions as a biological barrier by extruding toxic substances and xenobiotics out of cells. Drug efflux pumps such as P-gp play a functional role in determining the pharmacokinetics of drugs administered by oral and parenteral routes. Determining the activity of drug efflux transport proteins has important implications in the identification of substrates and/or inhibitors. The significant role of the small intestine in reducing the oral bioavailability of drugs is due to metabolic enzymes and efflux transporters. The role of cytochrome P-450 3A (CYP3A) and P-gp in intestinal drug disposition has been highlighted. This review examines the structure, localisation and functional role of P-gp, the mechanism of drug efflux and drug-herb interactions.
- 1 December 2010
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 25 (1-4) , 3-16
P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions
P-Glycoprotein (P-gp), the most extensively studied ATP-binding cassette transporter, functions as a biological barrier by extruding toxic substances and xenobiotics out of cells. Drug efflux pumps such as P-gp play a functional role in determining the pharmacokinetics of drugs administered by oral and parenteral routes. Determining the activity of drug efflux transport proteins has important implications in the identification of substrates and/or inhibitors. The significant role of the small intestine in reducing the oral bioavailability of drugs is due to metabolic enzymes and efflux transporters. The role of cytochrome P-450 3A (CYP3A) and P-gp in intestinal drug disposition has been highlighted. This review examines the structure, localisation and functional role of P-gp, the mechanism of drug efflux and drug-herb interactions.